SPORE in Lung Cancer

描述(申请人提供)：在过去的40年里，肺癌的5年存活率与所有癌症的5年存活率的提高保持同步。然而，它仍然令人失望地保持在-15%的低水平。5年存活率的提高是提高认识、更好的检测技术、更好地选择各种治疗方案的患者以及有选择地使用姑息性干预的结果。然而，肺癌死亡率仍然居高不下，这是后代判断我们能否有效抗击这种疾病的基准。肺癌中的莫菲特癌症中心孢子将1)阐明肺癌发生和肿瘤进展中的关键分子的作用机制，并调查它们对治疗效果的影响；2)前瞻性地评估这些分子在治疗和预防干预中的临床效用。我们的最终目标是改变对肺癌高危人群和肺癌患者的护理标准。孢子有五个翻译研究项目，三个核心，一个发展研究计划，和一个职业发展计划。 这些项目包括： 1)E2F对疗效的影响(Cress，Chen&Bepler) 2)RRM1在肺癌的管理中(Bepler，Cress&Simon) 3)肺癌中Src抑制剂的抗肿瘤机制(Haura，Cheng&Pledger) 4)苯扎托林的肺癌化学预防(Bepler&Alexandrow) 5)基于p53的小细胞肺癌疫苗(Gabrilovich&Antonia) 它们得到以下方面的支持： A)组织采购、病理学和生物信息学核心(Altiok&Fenstermacher) B)临床试验和生物统计学核心(Simon，Schell&Bepler) C)行政和患者倡导核心(Bepler，Cress&Quinn)。 孢子还设有发展研究和职业发展计划。这个孢子将被牢固地整合到H.Lee Moffitt癌症中心和研究所中，该中心是位于佛罗里达州坦帕市的一个独立的NCI指定的综合癌症中心。

DESCRIPTION (provided by applicant): The 5-year survival from lung cancer has kept pace with the improvement in 5-year survival from all cancers over the last 40 years. Yet, it remains disappointingly low at -15%. This improvement in 5-year survival is a result of heightened awareness, better technology for detection, better selection of patients for various therapeutic options, and the selective use of palliative interventions. However, lung cancer mortality remains extraordinarily high, and it is the benchmark by which future generations will judge our success in effectively combating this disease. The Moffitt Cancer Center SPORE in Lung Cancer will 1) elucidate mechanisms of action of crucial molecules in lung carcinogenesis and tumor progression and investigate their impact on therapeutic efficacy and 2) prospectively assess the clinical utility of the molecules for therapeutic and prevention interventions. Our ultimate goal is to change the standard of care for people at risk for and with lung cancer. The SPORE has five translational research projects, three cores, a developmental research program, and a career development program. The projects are: 1) E2Fs Impact on Therapeutic Efficacy (Cress, Chen & Bepler) 2) RRM1 in the Management of Lung Cancer (Bepler, Cress & Simon) 3) Antitumor Mechanisms of Src Inhibitors in Lung Cancer (Haura, Cheng & Pledger) 4) Lung Cancer Chemoprevention with Enzastaurin (Bepler & Alexandrow) 5) p53-Based Vaccine for Small Cell Lung Cancer (Gabrilovich & Antonia) They are support by: A) Tissue Procurement, Pathology, and Bioinformatics Core (Altiok & Fenstermacher) B) Clinical Trials & Biostatistics Core (Simon, Schell & Bepler) C) Administration & Patient Advocacy Core (Bepler, Cress & Quinn). The SPORE also has Developmental Research & Career Development Programs. This SPORE will be firmly integrated into the H. Lee Moffitt Cancer Center and Research Institute, a free-standing, NCI designated Comprehensive Cancer in Tampa, Florida.